Thursday
“Suppose we are working on a ‘big conjecture,’” proposed Professor Marcin Sabok, whose research focuses on a mathematical concept called ‘forcing.’ “We want to either prove that the big conjecture is true, or prove that the big conjecture is false. But what if neither of these can be done?”
Sabok stressed the precise mathematical definition of a proof and how it could be used to create alternative mathematical universes to better understand the logical process behind forcing, which is a way to prove independent mathematical results.
Professor Kaleem Siddiqi, a professor in the school of computer science, also talked about his interdisciplinary research, which stretches across geometry, biology, physics, and computer science. His focus: Shape analysis in medical imaging.
“In biology, patterns arise in anatomical structures,” Siddiqi said. “Here, we use physics. A certain technique in diffusion imaging [is used] to measure the direction in which water moves in myocytes. [It] is amazing […] that no myocyte knows the existence of any other myocyte, but collectively, they work together.”
Siddiqi highlighted a program called NSERC-CREATE in Medical Image Analysis, a research journal. The program is one of the first of its kind in Canada and aims to provide funding for research students while simultaneously providing them with the chance to apply their skills in an industrial environment.
Dr. David Dankort, an associate professor in the Department of Biology, works on mouse models to better understand RAS and BRAF, two prominent oncogenes responsible for many types of human cancer. An oncogene is any given gene that can potentially cause cancer, while a tumour suppressor gene works to safeguard a cell from cancerous mutations. Dankort’s lab, along with other cancer research labs also working on cancer pathways, is looking for ways to target both these genes in order to find treatments for cancers such as melanoma.
Dankort spoke about a drug called Vemurafenib, which inhibits BRAF in order to treat late-stage melanoma.
“While it works really well with people who have the BRAF mutation, 99 per cent of them will relapse,” he said. “At this point, they’re no longer treatable by the drug.”
Consequently, Dankort’s lab is consequently trying to discover a method to treat individuals who relapse—or to avoid relapse altogether—by targeting other genes within the BRAF pathway.
Professor Lisa-Marie Munter, an assistant professor in the pharmacology department, also researches disease treatment—specifically, Alzheimer’s disease. Her research differs, however, in that she focuses on alternative methods of drug development.
“Drug development is extremely expensive,” Munter said. “Researchers figured out that if people already went through toxicity qualifications [for developed drugs, they could] repurpose [them] for another disease.”
She cited thalidomide, which was originally developed as a sedative and morning sickness pill in the 1950s. Nowadays, it has been repurposed as a treatment for certain cancers instead.
“What I really like about science is that as a researcher, we can boldly go where no man has gone before,” Munter said.